---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316766"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2026-07-27T10:06:03+00:00"
generated_at: "2026-07-27T10:10:21.508537+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# argenx to acquire Forte Biosciences for $77/share (~$2.2B); adds anti-CD122 antibody FB102

## Summary
- argenx to acquire Forte Biosciences for $77/share in cash, total equity value ~$2.2B.
- Offer price represents ~86% premium to Forte's VWAP since positive Phase 1b vitiligo data on July 9, 2026.
- Acquisition adds first-in-class anti-CD122 antibody FB102 with clinical proof-of-concept in vitiligo and celiac disease.
- Forte board unanimously recommends; tender offer requires majority of shares tendered and HSR clearance.
- Supporting stockholders (directors/officers) owning ~1% of shares have agreed to tender.

## SEC filing metadata
- accession: 0001193125-26-316766
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2026-07-27T10:06:03+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/0001193125-26-316766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316766
- JSON: https://secwatch.observer/filing/0001193125-26-316766.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.